跳至主要内容
临床试验/NCT01540734
NCT01540734已完成1 期

A Single Dose PK Study Investigating the Extent of Paracetamol Absorption From Two Sustained Release Paracetamol Formulations

GlaxoSmithKline1 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2009年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
28
试验地点
1
主要终点
To compare bioavailability as measured by Area under the Curve in both fed and fasted states

研究概览

简要总结

A single dose pharmacokinetic study investigating two paracetamol formulations

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Good general heatlh with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination

排除标准

  • Subject does not agree to refrain from alcohol consumption for the 10-day period prior to visit 2 and throughout the remainder of the study.
  • Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
  • Current (within 14 days of screening) or regular use of any prescription, over the counter drugs including paracetamol/acetaminophen, herbal medicine or drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to dosing.

研究组 & 干预措施

Marketed paracetamol

Active Comparator

marketed formulation

干预措施: Marketed paracetamol (Drug)

Experimental paracetamol formulation

Experimental

Experimental formulation

干预措施: Experimental paracetamol formulation (Drug)

结局指标

主要结局

To compare bioavailability as measured by Area under the Curve in both fed and fasted states

时间窗: Visit 1 through Visit 3 (Day 13)

To assess the effect of food on extent and rate of paracetamol absorption as measured by Area Under the Curve and Cmax

时间窗: Visit 1 through Visit 3 (Day 13)

次要结局

  • To assess descriptive pharmacokinetic characteristics (Tmax, T1/2, AUC, Cmax)(Visit 1 through Visit 3 (Day 13))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验